Ipsen Says Iqirvo Secured FDA Accelerated Approval As First-In-Class PPAR Treatment For Primary Biliary Cholangitis; Iqirvo Was In-licensed From GENFIT In 2021
Portfolio Pulse from Benzinga Newsdesk
Ipsen announced that Iqirvo has secured FDA accelerated approval as the first-in-class PPAR treatment for primary biliary cholangitis. Iqirvo, an oral, once-daily PPAR agonist, was in-licensed from GENFIT in 2021.
June 10, 2024 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GENFIT, the original developer of Iqirvo, will benefit indirectly from the FDA accelerated approval secured by Ipsen, as it highlights the success of its drug development capabilities.
Although GENFIT is not the direct beneficiary of the FDA approval, the success of Iqirvo under Ipsen's license underscores GENFIT's drug development prowess, which could positively influence its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ipsen's Iqirvo has received FDA accelerated approval, marking a significant milestone for the company as it expands its portfolio with a first-in-class treatment for primary biliary cholangitis.
The FDA accelerated approval for Iqirvo is a significant achievement for Ipsen, likely to positively impact its stock price in the short term due to the addition of a first-in-class treatment to its portfolio.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100